Journal of Central Nervous System Disease (Nov 2021)

Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report

  • Afsaneh Shirani,
  • Scott R Dalton,
  • Eric J Avery,
  • Lakshman Arcot Jayagopal,
  • Christina Meyer,
  • Olaf Stuve,
  • Rana Zabad

DOI
https://doi.org/10.1177/11795735211053784
Journal volume & issue
Vol. 13

Abstract

Read online

A 48-year-old Caucasian woman with history of multiple sclerosis (MS) presented with erythematous papulonodular lesions in her extremities and trunk. She was being treated with glatiramer acetate (GA) for the past 10 years and the glatiramoid, Glatopa, for 2 years prior to this presentation. A skin biopsy showed CD30 + lymphoproliferative disorder consistent with lymphomatoid papulosis (LyP). Three weeks after stopping Glatopa, her skin lesions were improved. It remains unclear whether GA’s or Glatopa’s capability to alter T-cell differentiation, may have a link with LyP. This case report is a reminder to be vigilant for skin lesions in patients with MS.